Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Added: 1 year ago Source:  Radcliffe Cardiology
AUTHOR: Brad WilsonIn a study published in the Journal of the American College of Cardiology (JACC), Dr Elias Björnson and his colleagues demonstrated that lipoprotein(a) (Lp(a)) is approximately six times more atherogenic than low-density lipoprotein (LDL) per particle.Lp(a) is a lipoprotein particle that has long been recognised as a causal factor for coronary heart disease (CHD). However,… View more
Author(s): Harriette Van Spall , Michael C Gibson Added: 1 year ago
ACC 2024 — Late-breaker host, Dr Harriette Van Spall and Principal Investigator, Dr C Michael Gibson discuss the AEGIS-II trial (CSL Behring) (NCT03473223).This phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study investigated the efficacy and safety of an apolipoprotein A-I (apoA-I), CSL112 in patients with acute coronary syndrome (ACS). Investigators enrolled… View more
Author(s): Mirvat Alasnag , Khaled Al-Shaibi Added: 8 months ago
ESC Congress 24 – Day 4 of the ESC Congress 2024 was filled with hot line and late-breaking data poised to influence cardiovascular practice.Interventional experts DrMirvat Alasnagand DrKhaled Al-Shaibi(King Fahd Armed Forces Hospital, SA) joined us to review and distil the key messages from the latest data presented at the last of the biggest cardiovascular event of 2024.Day 4 Highlights:00:19… View more
Author(s): Brian Bergmark Added: 1 year ago
ACC.24 — Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) joins us in this interview to discuss the findings of a study into olezarsen, previously known as AKCEA-APOCIII-LRx, in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD), with or without severe hypertriglyceridemia (NCT05355402).This multicenter, randomized, double-blind study… View more